← ANALYST RATINGS · TIPRANKS
Eikon Therapeutics, Inc. (EIKN): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $29.00, the highest $32.00, the lowest $23.00. The average is +290.8% from the last price of $7.42.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Sara Nik★★★★★★★★★★#12104 · hits 16% · avg −17.8% | H.C. Wainwright | $23.00 | Buy | +210.0% | Initiated | 16.10.26on TipRanks 06:15 | −0.5% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $32.00 | Buy | +331.3% | Reiterated | 28.09.26on TipRanks 06:25 | +0.6%next day +0.2% · 5 days −5.9% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $32.00 | Buy | +331.3% | Assigned | 17.08.26on TipRanks 08:55 | −4.8%next day +11.9% · 5 days +7.8% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $29.00 | Buy | +290.8% | Reiterated | 17.08.26on TipRanks 07:53 | −4.8%next day +11.9% · 5 days +7.8% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $7.00 → $5.00−28.6% | Sell | −32.6% | Reiterated | 12.05.26on TipRanks 08:05 | +16.0%next day +6.2% · 5 days −7.1% | ↗ |
| Joseph Catanzaro★★★★★★★★★★#981 · hits 46% · avg +13.3% | Mizuho Securities | $26.00 | Buy | +250.4% | Initiated | 02.03.26on TipRanks 05:30 | +7.9%next day −6.4% · 5 days +1.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Eikon Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $31.00 at a price of $8.04 (+285.6%); now: $29.00 at $7.42 (+290.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 2 | 1 | 1 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Eikon Therapeutics, Inc.
- CEO: Roger Perlmutter
- Employees: 384
- 230 Harriet Tubman Way, Millbrae, CA, 94030, US
- eikontx.com
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Data from the stock’s TipRanks forecast page, read 146 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗